Recent Updates
Recently added Catalysts

PF-07264660

Phase 1

Healthy | Small molecule | Other |Pfizer, Inc.|Last Updated: Sep 25, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment12
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06712082A Study to Learn More About the Study Medicine PF-07264660 in Healthy Chinese Adult ParticipantsPHASE1 COMPLETED 12 — — Feb 24, 2025Sep 4, 2025Sep 25, 20252 China
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Maximum Observed Plasma Concentration (Cmax)
Up to Day 181
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Up to Day181
area under the concentration-time curve from time 0 to 336 hours (AUC336)
Up to Day 181
area under the concentration-time curve from time 0 to infinity (AUCinf)
Up to Day 181
area under the concentration-time curve from 0 to time of last measurable concentration (AUClast)
Up to Day 181
Terminal phase half-life (t½)
Up to Day 181
Incidence of treatment-emergent adverse events (TEAEs)
Up to Day 181
Incidence of treatment-emergent serious adverse events (SAEs)
Up to Day 181
Incidence of abnormal and clinically relevant changes in vital signs
Up to Day 181
Incidence of abnormal and clinically relevant changes in electrocardiogram
Up to Day 181
Incidence of abnormal and clinically relevant changes in laboratory assessments
Up to Day 181
Secondary Endpoints
Clearance (CL) of PF-07264660
Up to Day 181
volume of distribution (Vss)
Up to Day 181
mean residence time (MRT)
Up to Day 181
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeOTHER
Treatment Arms
ArmTypeDescription
PF-07264660EXPERIMENTALParticipants will receive a single dose of PF-07264660 via IV infusion
PlaceboPLACEBO_COMPARATORParticipants will receive a single dose of placebo via IV infusion
Interventions
NameTypeDescription
PF-07264660DRUGPF-07264660 solution for injection (single use only)
PlaceboOTHERPlacebo solution for injection (single use only)
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 65 Years
SexALL
Healthy VolunteersYes
Study Sites2

Inclusion Criteria: 1. Healthy male and female participants aged 18 to 65 years. 2. Body mass index (BMI) of 19-27.9 kilogram per meter squared, inclusive, and a total body weight \>50 kilograms (110 pounds). 3. Participants who are willing and able to comply with all scheduled visits, treatment pl...

Countries:China
Unlock Eligibility Criteria